Key result
Correction article reports no primary endpoint results or clinical trial outcomes.
Answers are grounded in this paper and cite their sources.
Enhanced microRNA-ML models may refine cardiotoxicity prediction in HER2+ breast cancer; leaves open prospective validation before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Anastasiou et al. (2026) studied HER2-positive breast cancer patients at risk for cardiotoxicity. MicroRNA signatures and machine learning models for predicting cardiotoxicity was evaluated. The correction article does not report primary endpoint results or clinical trial outcomes, so no effect size or quantitative result can be extracted.
Synapse has enriched 10 related papers. Consider them for comparative context: